Skip to content

Effect of Intraoperative Lidocaine Infusion on Postoperative Pain in Patients Undergoing Robotic-Assisted Radical Prostatectomy: A Randomized Controlled Trial

Effect of Intraoperative Lidocaine Infusion on Postoperative Pain in Patients Undergoing Robotic-Assisted Radical Prostatectomy: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250418004
Enrollment
69
Registered
2025-04-18
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Robotic-assisted radical laparoscopic prostatectomy is a minimally invasive procedure commonly used to treat prostate cancer. In recent years, the use of robotic-assisted radical prostatectomy (RARP) has significantly increased due to its numerous benefits, including smaller incisions, improved postoperative urinary continence, and reduced need for blood transfusions. However, despite these advantages, patients often experience significant immediate postoperative pain, largely attributed to int

Interventions

A bolus of lidocaine 1.5 mg/kg of ideal body weight or an equivalent volume of normal saline (NSS) is administered by the anesthetist during anesthetic drug induction. The intravenous infusion of lido
Experimental Drug,No Intervention Drug
Intraoperative lidocaine infusion,NSS infusion

Sponsors

Faculty of Medicine, Prince of Songkla University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: - Patients scheduled for elective robotic-assisted radical prostatectomy (RARP) - ASA classification I-III - Able to communicate and rate pain score as Verbal Numeric Rating Scale (VNRS) - Able to use intravenous patient-controlled analgesia (IV PCA)

Exclusion criteria

Exclusion criteria: - Known allergy to lidocaine or other amide local anesthetics - History of chronic pain requiring regular opioid or analgesic use within the past 3 months - Severe liver or renal disease CKD stage 4-5, Child-Pugh Class C, acute liver failure - Hypothyroidism - History of heart block, preexisting hypotension, or severe bradycardia with heart rate below 50 bpm - BMI exceeding 40 kg/m2 - History of Adam-Stoke Syndrome, Wolff-Parkinson-White Syndrome, Parkinson disease - Currently using specific medication, such as phenytoin, procainamide, tocainide,quinidine, beta-blocking agents, cimetidine - Family history of malignant hyperthermia

Design outcomes

Primary

MeasureTime frame
postoperative pain 0, 1, 2, 4, 12, 18 and 24 hours postoperatively Verbal numerical rating scale

Secondary

MeasureTime frame
postoperative fentanyl consumption 0, 1, 2, 4, 12, 18 and 24 hours postoperatively total fentanyl consumption,quality of recovery 24-48 hours postoperatively QoR-15 questionnaire,total length of hospital stay 1-2 weeks postoperatively total length of hospital stay (days)

Countries

Thailand

Contacts

Public ContactRatikorn Boonchai

Prince of Songkla University

r.boonyasith@gmail.com0896408984

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026